Why the study?
Does empagliflozin affect collagen biomarkers in patients with heart failure?
Does empagliflozin affect collagen biomarkers in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Empagliflozin down-regulates profibrotic signalling, which may mechanistically contribute to the clinical benefits of SGLT2 inhibitors in heart failure.
Our observations are consistent with experimental observations that empagliflozin down-regulates profibrotic signalling. The importance of such an effect for the clinical benefits of SGLT2i in HF remains to be elucidated.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: